肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2023年CSCO《乳腺癌诊疗指南》更新要点解读

2023-06-20 中国人民解放军总医院第五医学中心肿瘤医学部 中国肿瘤外科杂志 发表于上海

乳腺癌

该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。

中文标题：

2023年CSCO《乳腺癌诊疗指南》更新要点解读

发布机构：

中国人民解放军总医院第五医学中心肿瘤医学部

发布日期：

2023-06-20

简要介绍：

2023版CSCO乳腺癌诊疗指南基于循证医学证据和领域专家共识，考虑到国情及诊疗产品的可及性，在乳腺癌分类分层治疗的指导原则下，对乳腺癌的全程规范化治疗指南进行了更新和修订。该文总结了2023版CSCO乳腺癌诊疗指南早期乳腺癌部分的更新要点，并进行了详细解读。
 

相关资料下载：
2023年CSCO《乳腺癌诊疗指南》更新要点解读.pdf
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2024-03-07 中和制药东哥 来自湖南省

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-13 ms8000000455478267 来自江苏省

    如何获得积分下载？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-11-12 ms6000001473620636 来自广西

    对临床工作有很大指导意义！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-09-22 ms8000001769177689

    非常有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2191936, encodeId=dd78219193687, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 20:56:23 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2168217, encodeId=6135216821e1e, content=如何获得积分下载？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ebe8823147, createdName=ms8000000455478267, createdTime=Mon Nov 13 10:39:06 CST 2023, time=2023-11-13, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2168139, encodeId=b2b32168139f9, content=对临床工作有很大指导意义！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedb8199127, createdName=ms6000001473620636, createdTime=Sun Nov 12 16:45:16 CST 2023, time=2023-11-12, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2159100, encodeId=61a52159100cc, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d4b8182687, createdName=ms8000001769177689, createdTime=Fri Sep 22 10:49:35 CST 2023, time=2023-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152877, encodeId=d9ab21528e7c7, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36275141061, createdName=1467790cm53暂无昵称, createdTime=Tue Aug 15 14:53:00 CST 2023, time=2023-08-15, status=1, ipAttribution=浙江省)]
    2023-08-15 1467790cm53暂无昵称 来自浙江省

    有用

    0

相关指南

美国国家综合癌症网络临床实践指南：乳腺癌更新解读(2023V4)

哈尔滨医科大学附属肿瘤医院 · 2023-06-20

乳腺癌新辅助治疗中外指南对比解读

厦门大学附属翔安医院 · 2023-06-20

第三届关于乳房恶性潜在性不明的病变(B3病变)的国际共识会议

欧洲乳腺癌专科学会(EUSOMA,European Society of Breast Cancer Specialists) · 2023-06-17

2023 ASCO/CAP指南：人表皮生长因子受体2检测在乳腺癌中的应用（更新版）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2023-06-07

2023 ESMO共识声明：HER2低表达乳腺癌的定义，诊断和管理

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2023-06-01

乳腺癌患者芳香化酶抑制剂诱导的骨关节症状预防和管理的证据总结

复旦大学护理学院 · 2023-04-10

拓展阅读

European Radiology：DCE-MRI时间-强度曲线的体素绘制使乳腺病变的血流动力学异质性得以可视化和量化

动态增强磁共振成像 (DCE-MR）已成为最不可缺少的序列，能够显示整个肿瘤的三维血流动力学异质性，从而可以对病变进行极好的描述和定性。

《柳叶刀》：不用化疗，疗效不减！99%乳腺癌患者术后3年未复发

该研究表明HER2阳性转移性乳腺癌患者基于18F-脱氧葡萄糖正电子发射计算机断层扫描的pCR适应性策略，3年无浸润性疾病生存期（iDFS）可达到94.8%。

Cell Death & Disease：非酒精性脂肪肝竟会促进乳腺癌的发生！与这个因素有关

该研究强调了FGF21作为乳腺癌预后指标和潜在治疗靶点的临床意义，以及维持肝脏健康在乳腺癌预防和治疗中的重要性。

乳腺癌治疗三大利器，两大待攻克难题！浙江省肿瘤王晓稼等发表中国专题

《医学新视点》基于该特刊部分内容并结合当前乳腺癌相关管线进展，为读者带来乳腺癌领域重磅研究进展。

安徽医科大学朱勇/丁克硕团队ACS Nano:揭示多壁碳纳米管暴露促进乳腺癌转移机制

通过构建乳腺癌细胞/巨噬细胞共培养体系揭示了MWCNTs暴露促进巨噬细胞M2极化，进而易化乳腺癌的肺部转移和克隆化生长，并从表观遗传学角度阐明其中的分子机制。

安徽医科大学朱勇/丁克硕团队《ACS Nano》揭示多壁碳纳米管暴露促进乳腺癌转移机制

通过构建乳腺癌细胞/巨噬细胞共培养体系揭示了MWCNTs暴露促进巨噬细胞M2极化，进而易化乳腺癌的肺部转移和克隆化生长，并从表观遗传学角度阐明其中的分子机制。

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组（统称） · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识（2010版）

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议：乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南：乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南：激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12